NTRA News and Press, Natera Inc. From 10/28/21

Natera Announces Third Quarter 2021 Earnings Conference Call PR Newswire AUSTIN, Texas , Oct. 28, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, today announced that it will release r...

Natera Expands Organ Health Business With Commercial Launch of the Prospera™ Lung Transplant Assessment Test Results of VALID study presented at CHEST 2021 yield an AUC of 0.91 for Prospera Lung PR Newswire AUSTIN, Texas , Oct. 18, 2021 /PRNewswire/ --...

Natera Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer Management Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by Signatera in over 1200 plasma samples PR Newswire...

Natera Announces Completion of the Largest Prospective Validation Study of a Commercial Cell-Free DNA Test in Lung Transplantation Results from the VALID study accepted for presentation of late breaking abstract at premier CHEST conference PR Newswire AUSTIN, Texas...

Court Rules in Natera's Favor Invalidating All of CareDx's Asserted Patents PR Newswire AUSTIN, Texas , Sept. 29, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), is pleased that the Delaware Federal District Court ruled today that all three patents Care...

Shares of Natera Inc. (NASDAQ:NTRA) traded at a new 52-week high today of $128.80. So far today approximately 118,000 shares have been exchanged, as compared to an average 30-day volume of 585,000 shares. Natera Inc. (NASDAQ:NTRA) is currently priced 23.7% above its average consensus ana...

Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma Data suggests that ctDNA dynamics may be a better surrogate of overall survival than radiographic imaging (RECIST criteria) PR Newswire AUSTIN, Texas , Sept. 17, 2021 ...

Natera Launches Prospera™ Kidney with Quantification to Further Improve Test Performance, Demonstrating Commitment to Innovation in Transplantation Validation study published in the Journal of the American Society of Nephrology (JASN) showed improved sensitivity with quan...

Healthcare had a slow start but now is one of the leading sectors in terms of 2021 performance. Healthcare is well-positioned to benefit from growing spending and pent-up demand. The sector is also a defensive investment if economic growth concerns mount. Regulatory risk remai...

Natera's Signatera® Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer Pivotal clinical trial aims to establish a new standard of care for stage II and III colon cancer patients PR Newswire AUSTIN,...